Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-Lipoic Acid in ICU Patients
NCT01888861Phase 3Unknown
- Start
- Feb 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha-lipoic acid in oxidative stress, inflammation and Malnutrition. Primary endpoints: Length of Stay in ICU at 28 days and Mortality at 28 days. Status: unknown.
02
Drugs
alpha-lipoic acid
03
Conditions
oxidative stressinflammationMalnutrition
Beyond the preview
Go deeper on NCT01888861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01888861.